Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
Multiple Myeloma: Elderly Patients

Multiple Myeloma: Elderly Patients

Multiple Myeloma: High Risk Cytogenetics

Multiple Myeloma: High Risk Cytogenetics

Multiple Myeloma: Renal Impairment

Multiple Myeloma: Renal Impairment

Lenalidomide Refractory Patients

Lenalidomide Refractory Patients

Multiple Myeloma: Minimal Residual Disease

Multiple Myeloma: Minimal Residual Disease

Multiple Myeloma: Chromosome 1q+ cytogenetic abnormalities

Multiple Myeloma: Chromosome 1q+ cytogenetic abnormalities

Gaucher disease awareness month video

Gaucher disease awareness month video

What can biologic treatment do for patients with CRS with nasal polyps?

What can biologic treatment do for patients with CRS with nasal polyps?

Rethink Your Nasal Polyps. Type 2 Inflammation A Nasal Polyp Mystery

Rethink Your Nasal Polyps. Type 2 Inflammation A Nasal Polyp Mystery

Pneumology Meets Oto-Rhino-Laryngology: A Discussion of Type 2 Inflammation in Airway Diseases

Pneumology Meets Oto-Rhino-Laryngology: A Discussion of Type 2 Inflammation in Airway Diseases

Hear From An Expert On Would You Consider A Biologic For A Surgery-Naïve Patient With Crs With Nasal Polyps?

Hear From An Expert On Would You Consider A Biologic For A Surgery-Naïve Patient With Crs With Nasal Polyps?

Type 2 Inflammation Is The Underlying Cause Of Crswnp In 80% Of Patients.

Type 2 Inflammation Is The Underlying Cause Of Crswnp In 80% Of Patients.